Journal: Journal of Personalized Medicine
Article Title: Protection Against Cellular Toxicity from Rotenone Treatment by the Neuroprotective, Novel Multifunctional Antiparkinsonian Drug D-512
doi: 10.3390/jpm16020115
Figure Lengend Snippet: Western blot studies on the effect of D-512 in decreasing ERK activity induced by rotenone toxicity: PC12 cells were treated with 1µM rotenone for different time points (30 min, 1 h, 2 h, 4 h, 6 h) ( A , C ). Dose-dependent effect of pretreatment with D-512, followed by co-treatment with rotenone on ERK levels in PC12 cells. PC12 cells were pretreated with different doses of D-512 (10 µM and 5 µM) for 24 h, followed by co-treatment with 1 μM rotenone for 30 min. The membranes were probed with p-ERK and t-ERK antibodies ( B , D ). Actin was used as a loading control. Values shown are means ± SDs of three independent experiments. One-way ANOVA analysis followed by Tukey’s multiple comparison post hoc test was performed. For ( C ) F (5, 12) = 6.93, ** p < 0.01 compared to the control, and for ( D ) F (4, 10) = 11.41, ** p < 0.01 compared to the rotenone.
Article Snippet: Rat adrenal pheochromocytoma PC12 cell lines (ATCC, Manassas, VA, USA, CRL1721.1TM) cells were purchased from ATCC.
Techniques: Western Blot, Activity Assay, Control, Comparison